Hair Loss on AAS: DHT, Genetics, and What Bloodwork Shows

Your training partner runs 500 mg of testosterone per week and keeps his hairline. You run 200 mg and start shedding in week 3. The difference is not your protocol, it is your genes. Hair loss on androgenic compounds is almost entirely determined by genetic sensitivity to dihydrotestosterone (DHT), and understanding that sensitivity separates preventable shedding from inevitable baldness.

The genetic component is not just about the AR gene. The enzyme 5α-reductase also has genetic variability. Type II 5α-reductase is the dominant form in scalp tissue, and its activity varies between individuals. Some men have higher baseline scalp 5α-reductase activity, meaning even modest testosterone doses produce more local DHT. This is why two people with identical CAG repeat lengths can respond differently to the same compound. If you want a more precise risk assessment, consider testing baseline DHT and SHBG before starting any cycle. A DHT above 60 ng/dL with a SHBG below 20 nmol/L suggests you are a high converter, and even low-dose testosterone will put your scalp under pressure.

The DHT Mechanism: Testosterone's More Potent Metabolite

Testosterone gets converted into DHT by the enzyme 5α-reductase, and that enzyme is concentrated in the scalp, prostate, and skin. DHT then binds the androgen receptor with roughly 2-4 times the affinity of testosterone itself, which makes it a far more potent signal in any tissue where 5α-reductase is doing its work.

5α-reductase exists in two main isoforms. Type I is found in sebaceous glands and skin, while type II dominates the scalp and prostate. Finasteride inhibits type II only, which is why it reduces scalp DHT but not completely. Dutasteride inhibits both, which is why it is more effective for hair but also more likely to cause libido and erectile side effects. The clinical difference is significant: finasteride lowers serum DHT by about 70%, dutasteride by over 90%. For TRT patients, this means finasteride leaves enough DHT for some androgen signaling, while dutasteride can push DHT into castrate territory. If you are on dutasteride and experience persistent erectile dysfunction, the half-life of 5 weeks means side effects can last months after discontinuation.

In the scalp, DHT binds to androgen receptors in dermal papilla cells: the cells that regulate hair follicle growth. In genetically sensitive individuals, this binding triggers a progressive shortening of the anagen (growth) phase and miniaturization of the follicle. Each hair cycle produces a thinner, shorter hair until the follicle eventually stops producing visible hair entirely.

The genetic key is a sequence in the androgen receptor gene called the CAG repeat. Shorter CAG repeats produce a more sensitive androgen receptor, so the same DHT level generates a stronger signal. Men with shorter CAG repeats are significantly more likely to develop male pattern baldness, both naturally and under AAS. That also explains why some guys lose hair on 200 mg of testosterone while others keep their hair on 500 mg. It is not fairness, it is CAG repeat length.

CAG repeat length is not just a binary short or long. The average is around 22 repeats. Men with fewer than 17 repeats are considered highly sensitive, while those with more than 25 are relatively resistant. This variation explains why some men can run 500 mg of testosterone weekly for years without visible thinning, while others shed on 150 mg. The clinical implication is that if you have a family history of MPB, you likely have shorter CAG repeats. You can get your CAG repeat length tested through a commercial genetic panel, but the result is not a guarantee. It is a probability modifier. Even with long repeats, high doses of trenbolone or masteron can overwhelm the receptor and trigger shedding.

Compound Impact on Hair: Androgenic Affinity Ranking

Not all AAS compounds affect hair equally, and the key variable is the compound's androgenic binding affinity: how strongly it binds the androgen receptor. Compounds that are structural derivatives of DHT (like masteron and winstrol) have high androgenic affinity, while compounds with a modified structure that reduces androgenic binding (like nandrolone and primobolan) are significantly milder.

Nandrolone actually converts to dihydronandrolone (DHN), a weak androgen, rather than DHT. That's what makes it one of the mildest compounds for hair, and a go-to for guys who are genetically predisposed to hair loss but still want to run a compound cycle. That said, individual response still varies, and some users report shedding on nandrolone despite the favorable pharmacology.

Nandrolone is mild for hair because DHN binds the AR with about 10% of DHT's affinity. But there is a catch: nandrolone suppresses your natural testosterone production, so it is typically run alongside a testosterone base, and that base still converts to DHT — the specific doses of each are a protocol decision, not something to copy from an article. However, nandrolone has its own side effects: it can raise prolactin and cause progesterone-like effects. Monitor your E2 and prolactin on cycle, not just your hairline, and bring any AI decision to whoever manages your protocol.

Blood Markers Relevant to Hair Loss

Three blood markers give you a clear read on your hair loss risk and point you toward the right intervention strategy.

DHT serum levels: While DHT is primarily a local (paracrine) hormone, serum DHT correlates with scalp DHT activity in most individuals. A baseline DHT measurement before starting compounds tells you where you start. On AAS, elevated DHT confirms that 5α-reductase is active. If you are shedding and your DHT is in range despite high testosterone, the shedding is likely driven by direct AR binding from the compound itself rather than from converted DHT.

Serum DHT is a useful baseline, but it does not tell you about local scalp conversion. A normal serum DHT range is 30-85 ng/dL. On a higher testosterone dose, serum DHT can double or triple. If your baseline is already at the high end, you are at greater risk. The best time to test DHT is 4-6 weeks into a cycle, when steady state is reached. If your DHT is markedly elevated and you are shedding, that finding — and whether the answer is a dose change or a 5α-reductase inhibitor — is worth bringing to a licensed medical professional or dermatologist rather than deciding yourself; combining finasteride and dutasteride, for instance, can crash DHT further than either one alone and cause more side effects than hair benefit, which is exactly the kind of tradeoff a clinician should weigh in on.

Low SHBG means more free (unbound) testosterone is available for 5α-reductase conversion to DHT. Androgenic compounds suppress SHBG pharmacologically, which increases free androgen fractions. When SHBG drops below 15 nmol/L on cycle, the amount of testosterone available for DHT conversion amplifies, potentially accelerating hair loss in sensitive individuals.

Ferritin and iron status: This is the most overlooked marker in hair loss. Ferritin below 40 ng/mL is associated with telogen effluvium: a form of shedding caused by nutrient deficiency rather than androgen activity. If you are losing hair and your ferritin is low, correcting iron status may reduce shedding significantly, even without addressing the androgen component. Check ferritin, serum iron, TIBC, and transferrin saturation before assuming DHT is the only factor.

Ferritin below 40 ng/mL is a red flag, but the optimal range for hair growth is 70-100 ng/mL. Many athletes run ferritin in the 20-30 range because of frequent blood donations or poor iron intake. If you are shedding and your ferritin is low, iron repletion is worth discussing with a licensed medical professional — the right dose and schedule depend on how low it is and why, and excess iron carries its own oxidative-stress risk, so this isn't a supplement to dose by guesswork. Recheck ferritin after repletion starts. If it does not rise, investigate other causes like gastrointestinal bleeding or training-induced hemolysis. Iron repletion takes 3-4 months to show visible hair improvement, so be patient.

Prevention and Intervention Options

The androgenic-affinity differences between compounds described above are one reason genetically sensitive users often see far less shedding on lower-androgen compounds than on high-affinity ones like trenbolone and masteron. That said, which compound to use is a personal decision with its own tradeoffs beyond hair, and none of this is a recommendation to use any particular substance — it is context for understanding why the same person's hair responds so differently to different compounds.

Finasteride (1 mg/day) blocks type II 5α-reductase, reducing DHT conversion by approximately 70%. For TRT patients, finasteride effectively prevents testosterone from converting to DHT in the scalp. The trade-off: serum DHT drops, and some users experience a compensatory rise in estradiol because more testosterone is available for aromatization. If you are prone to high E2 symptoms, monitor estradiol 4-6 weeks after starting finasteride.

Finasteride is not a free pass. It reduces DHT systemically, which can cause a compensatory rise in testosterone and estradiol. Some men see their E2 climb by 20-30% because more testosterone is available for aromatase. This can lead to water retention, mood swings, and gyno symptoms, which is worth flagging to whoever manages your AI dosing if you're on one when starting finasteride. Also, finasteride does not block DHT already bound to the receptor. It only prevents new conversion. This means it takes 3-6 months to see full effect, and shedding may initially increase as the hair cycle resets. Do not stop finasteride after 2 weeks because you see more shedding. That is a normal response.

Taking 0.5 mg per day, Dutasteride blocks both type I and type II 5α-reductase, dropping DHT by over 90%. It does a better job at preserving hair, but that comes with a higher risk of side effects, including a more pronounced E2 shift. And because its half-life is about 5 weeks, side effects linger longer after you discontinue.

Minoxidil (5% topical, once or twice daily) prolongs the anagen phase and increases blood flow to the follicle. It works independently of androgen signaling, so it can be used alongside any compound. Results take 3-6 months to appear, and shedding often increases in the first 4-6 weeks as the follicle cycle resets. This initial shed is not a sign that hair loss is worsening: it is the drug working.

When to Worry: Diffuse Thinning vs. MPB Pattern

Shedding while on AAS doesn't automatically mean male pattern baldness. The way the hair falls out, the pattern of it, is what separates androgen-driven loss from something else entirely.

The pattern of shedding is your first diagnostic clue. MPB is a slow, progressive recession at the temples and crown, often over years. Telogen effluvium is a sudden, diffuse shedding that happens 2-3 months after a trigger like a crash diet, surgery, or a rapid hormone shift. On AAS, a rapid increase in testosterone or a switch to a highly androgenic compound can push a large number of follicles into telogen simultaneously. This is why you might see clumps of hair in the shower within 3-4 weeks of starting trenbolone. That is not MPB; it is a stress response. If you catch it early, the hair often regrows once the hormone levels stabilize. Do not panic and stop the cycle immediately. Give it 4-6 weeks to see if the shedding slows.

MPB pattern: Recession at the temples and thinning at the crown. This is androgen-driven and predictable. It will progress if you continue using androgenic compounds without intervention. It is often not fully reversible, even after stopping compounds.

Diffuse thinning: Hair loss spread evenly across the scalp, without a clear MPB pattern. This can be caused by telogen effluvium (stress, nutrient deficiency, rapid hormone shifts), thyroid dysfunction, or iron deficiency. Diffuse thinning is frequently reversible once the underlying cause is addressed. If you notice clumps of hair in the shower but no clear recession pattern, check ferritin, TSH, and free T3 before reaching for finasteride.